Medical history is full of wrong conclusions drawn from “appears to work” observations — bloodletting included centuries of observational “evidence.” Observational research’s fundamental limitation is confounding: patients who receive a treatment may differ systematically from those who don’t in ways that produce apparent treatment effects.
## Why Randomized Controlled Trials (RCTs) Matter
**Randomization** allocates participants to treatment and control groups randomly, balancing known and unknown confounders across groups at scale, making observed outcome differences more likely to be genuinely caused by the intervention.
**Control groups**: placebo control is the most rigorous design, excluding the placebo effect. Active control compares a new drug against existing standard of care — appropriate when effective treatments already exist.
**Blinding**: single-blind (participant unaware of group assignment); double-blind (participant and researcher both unaware — most common gold standard); triple-blind (data analysts also unaware of group assignment).
## Endpoint Selection
**Primary endpoint**: the core measure of efficacy; pre-registered; statistical power calculated around it. Common types: hard endpoints (all-cause mortality, myocardial infarction, stroke — objective and incontestable; regulators most prefer these); surrogate endpoints (blood pressure, HbA1c, tumor shrinkage — correlated with hard endpoints but not the outcomes patients care about; FDA accepts for accelerated approval, but full approval typically requires hard endpoint data).
**Secondary endpoints**: supplementary questions with insufficient statistical power for standalone conclusions; results require cautious interpretation.
**Patient-Reported Outcomes (PROs)**: quality of life, symptom scores — directly reflecting patient experience; growing importance in regulatory decisions.
## Quick Research Quality Assessment
1. Randomized and double-blind? (check ClinicalTrials.gov or WHO ICTRP registration)
2. Primary endpoint pre-registered? (prevents post-hoc endpoint changes to manufacture positive results)
3. Adequate sample size? (statistical power ≥80%)
4. Acceptable dropout rate? (generally <20%)
5. Conflicts of interest disclosed? (pharmaceutical company sponsors require additional scrutiny)
See [Precision Medicine](https://sunqi.org/precision-medicine-genomics-en/), [CRA Career](https://sunqi.org/clinical-research-associate-career-en/), and [ClinicalTrials.gov](https://clinicaltrials.gov/).
